Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes
Adv Ther 39 , 24522467 (2022)
Forty received oral semaglutide, 32 received injectable semaglutide, 12 received dulaglutide, while 8 received liraglutide (see Figure 2)
This suggests that these hormones have pleiotropic effects beyond lowering blood glucose levels [9,10,11]
Testing documentation varies by sellable lot
Liraglutide, a glucagon-like peptide-1 receptor agonist, facilitates osteogenic proliferation and differentiation in MC3T3-E1 cells through phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT), extracellular signal-related kinase (ERK)1/2, and cAMP/protein kinase A (PKA) signaling pathways involving -catenin